| Literature DB >> 32316686 |
Beatriz Navarro-Brazález1, Virginia Prieto-Gómez1, David Prieto-Merino1,2, Beatriz Sánchez-Sánchez1, Linda McLean3, María Torres-Lacomba1.
Abstract
Hypopressive exercises have emerged as a conservative treatment option for pelvic floor dysfunction (PFD). The aim of this study was to compare the effects of an eight-week hypopressive exercise program to those of an individualized pelvic floor muscle (PFM) training (PFMT) program, and to a combination of both immediately after treatment and at follow-up assessments at 3, 6 and 12 months later. The study was a prospective, single-centre, assessor-blinded, randomised controlled trial. Ninety-four women with PFD were assigned to PFMT (n = 32), hypopressive exercises (n = 31) or both (n = 31). All programs included the same educational component, and instruction about lifestyle interventions and the knack manoeuvre. Primary outcomes were the Pelvic Floor Distress Inventory Short Form (PFDI-20); the Pelvic Floor Impact Questionnaire Short Form (PFIQ-7); PFM strength (manometry and dynamometry) and pelvic floor basal tone (dynamometry). There were no statistically significant differences between groups at baseline, nor after the intervention. Overall, women reduced their symptoms (24.41-30.5 on the PFDI-20); improved their quality of life (14.78-21.49 on the PFIQ-7), improved their PFM strength (8.61-9.32 cmH2O on manometry; 106.2-247.7 g on dynamometry), and increased their pelvic floor basal tone (1.8-22.9 g on dynamometry). These data suggest that individual PFMT, hypopressive exercises and a combination of both interventions significantly reduce PFD symptoms, enhance quality of life, and improve PFM strength and basal tone in women with PFD, both in the short and longer term.Entities:
Keywords: adherence; hypopressive exercises; pelvic floor dysfunction; pelvic floor exercise; physiotherapy; quality of life
Year: 2020 PMID: 32316686 PMCID: PMC7230910 DOI: 10.3390/jcm9041149
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1Flow diagram of participants.
Baseline characteristics of women.
| Characteristics | PFMT Group | HE Group | PFMT+HE Group | Total Sample |
|---|---|---|---|---|
| Age years, (SD) | 48 (12) | 48 (8) | 46 (8) | 47 (10) |
| BMI kg/m2, (SD) | 24.39 (4.77) | 24.63 (3.72) | 26.21 (4.73) | 25.07 (4.47) |
| Menopause, | 14 (44%) | 10 (32%) | 10 (32%) | 34 (36%) |
| Parity, (SD) | 2 (1) | 2 (1) | 2 (1) | 2 (1) |
| Smoking, | 2 (6.3%) | 8 (25.8%) | 7 (22.6%) | 17 (18.1%) |
| High blood pressure, | 2 (6.3%) | 2 (6.5%) | 2 (6.5%) | 6 (6.4%) |
| Depression, | 4 (12.5%) | 3 (9.7%) | 7 (22.6%) | 14 (14.9%) |
| Respiratory disease, | 3 (9.4%) | 8 (25.8%) | 3 (9.7%) | 14 (14.9%) |
| Constipation, | 10 (31.3%) | 14 (45.2%) | 10 (32.3%) | 34 (36.2%) |
| Physical activity, | 24 (75%) | 24 (77.4%) | 21 (67.7%) | 69 (73.4%) |
| Pelvic floor dysfunction | 94 (100%) | |||
| UI, | 27 (84.4%) | 26 (83.9%) | 26 (83.9%) | 79 (84.0%) |
| AI, | 13 (56.3%) | 17 (54.8%) | 9 (29.0%) | 44 (46.8%) |
| POP, | 13 (40.6%) | 11 (35.5%) | 19 (61.3%) | 43 (45.7%) |
| Previous PF surgery, | 3 (9.4%) | 4 (12.9%) | 1 (3.4%) | 8 (8.5%) |
| PFDI-20 total, (DE) | 71.71 (45.22) | 70.20 (35.23) | 69.19 (51.62) | 70.38 (44.08) |
| POPDI, (SD) | 18.49 (14.58) | 17.61 (14.34) | 22.45 (21.05) | 19.50 (16.87) |
| CRADI, (SD) | 16.51 (18.26) | 20.47 (14.57) | 14.22 (12.07) | 17.06 (15.27) |
| UDI, (SD) | 36.72 (21.93) | 32.12 (21.44) | 32.53 (25.22) | 33.82 (22.76) |
| PFIQ-7 V0 total, (SD) | 45.39 (43.71) | 32.26 (31.36) | 35.48 (28.57) | 37.79 (35.34) |
| POPIQ, (SD) | 11.16 (16.96) | 7.68 (12.94) | 9.37 (13.72) | 9.42 (14.58) |
| CRAIQ, (SD) | 11.31 (18.09) | 4.15 (9.18) | 4.91 (8.65) | 6.84 (13.07) |
| UIQ, (SD) | 22.92 (19.52) | 20.43 (19.87) | 21.20 (19.02) | 21.53 (19.29) |
| LAT grade | ||||
| 0, | 3 (9.4%) | 1 (3.2%) | 3 (9.7%) | 7 (7.4%) |
| 1, | 4 (12.5%) | 2 (6.5%) | 6 (19.4%) | 12 (12.8%) |
| 2, | 5 (15.6%) | 2 (6.5%) | 4 (12.9%) | 11 (11.7%) |
| 3, | 15 (46.9%) | 15 (48.4%) | 11 (35.5%) | 41 (43.6%) |
| 4, | 4(12.5%) | 10 (32.3%) | 7 (22.6%) | 21 (22.3%) |
| 5, | 1 (3.1%) | 1 (3.2%) | 0 (0.0%) | 2 (2.1%) |
| Manometry cmH2O, (SD) | 16.51 (14.19) | 22.87 (15.92) | 18.0 (13.86) | 19.11 (14.76) |
| Dynamometry g, (SD) | 239.16 (216.10) | 370.20 (307.03) | 268.74 (216.63) | 293.55 (254.57) |
| Basal tone g, (SD) | 206.67 (17.80) | 204.13 (13.70) | 200.47 (15.73) | 203.76 (15.84) |
| Nearby muscles contraction, | 27 (84.4%) | 23 (74.2%) | 25 (77.4%) | 74 (78.7%) |
| Apnea during PFM contraction, | 27 (84.4%) | 17 (54.8%) | 25 (80.6%) | 69 (73.4%) |
PFMT: Pelvic floor muscle training; HE: Hypopressive exercises; PFMT+HE: Pelvic floor muscle training and hypopressive exercises; n: Number; SD: Standard deviation; BMI: Body mass index; UI: Urinary incontinence; AI: Anal incontinence; POP: Pelvic organ prolapse; PF: Pelvic floor; PFDI-20: Pelvic floor Distress Inventory Short Form; POPDI: Pelvic organ prolapse distress inventory; UDI: Urinary distress inventory; CRADI: Colo-rectal-anal distress inventory; PFIQ-7: Pelvic Floor Impact Questionnaire Short Form; POPIQ: Prolapse impact questionnaire; CRAIQ: Colo-rectal-anal impact questionnaire; UIQ: Urinary impact questionnaire; LAT: Levator Ani Testing; PFM: Pelvic floor muscles. There were no found significant differences between groups.
Average changes for each outcome between baseline measurement and different periods (adjusted by baseline).
| Variable | To | PFMT Group | HE Group | PFMT+HE Group | |||
|---|---|---|---|---|---|---|---|
| Mean | 95%CI | Mean | 95%CI | Mean | 95%CI | ||
| PFDI-20 | A1 | −30.55 | (−40.70 to −20.39) | −32.17 | (−42.48 to −21.86) | −24.41 | (−34.72 to −14.09) |
| PFDI-20 | A2 | −35.07 | (−46.63 to −23.52) | −34.30 | (−46.03 to −22.57) | −25.24 | (−36.98 to −13.50) |
| PFDI-20 | A3 | −39.49 | (-49.86 to −29.11) | −40.80 | (−51.34 to −30.27) | −24.71 | (−35.25 to −14.17) |
| PFDI-20 | A4 | −41.70 | (−51.61 to −31.78) | −41.69 | (−51.76 to −31.62) | −25.77 | (−35.85 to −15.69) |
| POPDI | A1 | −7.95 | (−11.83 to −4.07) | −9.07 | (−13.04 to −5.10) | −5.82 | (−9.79 to −1.84) |
| POPDI | A2 | −8.24 | (−12.84 to −3.63) | −8.49 | (−13.20 to −3.78) | −4.75 | (−9.46 to −0.03) |
| POPDI | A3 | −9.44 | (−13.22 to −5.66) | −10.84 | (−14.71 to −6.98) | −6.77 | (−10.64 to −2.90) |
| POPDI | A4 | −13.11 | (−16.94 to −9.29) | −10.58 | (−14.49 to −6.67) | −6.10 | (−10.02 to −2.18) |
| CRADI | A1 | −5.91 | (−9.42 to −2.40) | −7.28 | (−10.95 to −3.62) |
|
|
| CRADI | A2 | −7.54 | (−11.58 to −3.49) | −6.53 | (−10.75 to −2.30) | −5.50 | (−9.73 to −1.28) |
| CRADI | A3 | −9.44 | (−12.74 to −6.15) | −8.72 | (−12.16 to −5.28) | −5.76 | (−9.21 to −2.32) |
| CRADI | A4 | −8.17 | (−11.66 to −4.67) | −9.57 | (−13.22 to −5.92) | −4.21 | (−7.86 to −0.56) |
| UDI | A1 | −15.83 | (−21.45 to −10.22) | −15.74 | (−21.41 to −10.06) | −15.11 | (−20.77 to −9.44) |
| UDI | A2 | −21.06 | (−26.44 to −15.69) | −17.03 | (−22.46 to −11.60) | −14.62 | (−20.04 to −9.20) |
| UDI | A3 | −20.30 | (−25.82 to −14.77) | −21.21 | (−26.80 to −15.63) | −12.99 | (−18.56 to −7.42) |
| UDI | A4 | −20.57 | (−25.29 to −15.84) | −21.44 | (−26.21 to −16.67) | −15.77 | (−20.54 to −11.01) |
| PFIQ-7 | A1 | −21.49 | (−30.60 to −12.38) | −18.73 | (−28.00 to −9.47) | −14.78 | (−23.93 to −5.64) |
| PFIQ-7 | A2 | −26.14 | (−34.83 to −17.45) | −25.01 | (−33.84 to −16.18) | −12.21 | (−20.93 to −3.48) |
| PFIQ-7 | A3 | −26.6 | (−33.46 to −19.74) | −26.17 | (−33.14 to −19.19) | −18.50 | (−25.39 to −11.62) |
| PFIQ-7 | A4 | −26.69 | (−33.79 to −19.58) | −23.22 | (−30.44 to −16.00) | −14.41 | (−21.55 to −7.28) |
| POPIQ | A1 | −5.57 | (−9.86 to −1.27) | −5.01 | (−9.39 to −0.63) |
|
|
| POPIQ | A2 | −7.92 | (−11.94 to −3.90) | −6.29 | (−10.39 to −2.19) |
|
|
| POPIQ | A3 | −7.30 | (−10.15 to −4.45) | −6.16 | (−9.07 to −3.26) | −4.03 | (−6.91 to −1.15) |
| POPIQ | A4 | −6.88 | (−9.68 to −4.09) | −6.02 | (−8.87 to −3.17) |
|
|
| CRAIQ | A1 | −5.17 | (−8.49 to −1.86) | −3.98 | (−7.39 to −0.57) |
|
|
| CRAIQ | A2 | −5.36 | (−9.11 to −1.61) | −4.49 | (−8.34 to −0.63) |
|
|
| CRAIQ | A3 | −5.65 | (−7.78 to −3.53) | −4.81 | (−7.00 to −2.62) | −2.53 | (−4.68 to −0.38) |
| CRAIQ | A4 | −6.01 | (−8.05 to −3.97) | −2.35 | (−4.45 to −0.26) |
|
|
| UIQ | A1 | −11.05 | (−15.13 to −6.97) | −10.9 | (−15.04 to −6.75) | −10.13 | (−14.27 to −6.00) |
| UIQ | A2 | −13.45 | (−17.19 to −9.70) | −14.31 | (−18.11 to −10.51) | −11.18 | (−14.97 to −7.39) |
| UIQ | A3 | −13.70 | (−17.30 to −10.10) | −15.00 | (−18.65 to −11.35) | −12.48 | (−16.13 to −8.83) |
| UIQ | A4 | −13.40 | (−17.61 to −9.19) | −14.75 | (−19.02 to −10.48) | −10.55 | (−14.81 to −6.28) |
| Manometry | A1 | 9.32 | (6.03 to 12.61) | 8.70 | (5.37 to 12.03) | 8.61 | (5.41 to 11.80) |
| Manometry | A2 | 9.36 | (5.97 to 12.75) | 7.10 | (3.67 to 10.53) | 10.12 | (6.83 to 13.41) |
| Manometry | A3 | 9.30 | (5.88 to 12.71) | 7.25 | (3.80 to 10.70) | 8.50 | (5.19 to 11.82) |
| Manometry | A4 | 9.31 | (5.44 to 13.18) | 8.46 | (4.55 to 12.37) | 9.88 | (6.12 to 13.63) |
| Dynamometry | A1 | 247.68 | (175.12 to 320.23) | 106.18 | (35.12 to 177.23) | 153.84 | (85.02 to 222.65) |
| Dynamometry | A2 | 225.28 | (154.72 to 295.84) | 121.12 | (51.74 to 190.49) | 132.80 | (63.98 to 201.62) |
| Dynamometry | A3 | 225.80 | (141.85 to 309.76) | 152.09 | (68.36 to 235.83) | 149.98 | (68.10 to 231.87) |
| Dynamometry | A4 | 216.68 | (132.01 to 301.34) | 181.80 | (98.56 to 265.05) | 174.22 | (91.65 to 256.80) |
| Basal tone | A1 |
|
|
|
|
|
|
| Basal tone | A2 | 4.09 | (0.27 to 7.91) | 7.6 | (3.90 to 11.30) |
|
|
| Basal tone | A3 |
|
|
|
| 22.87 | (6.82 to 38.91) |
| Basal tone | A4 | 9.08 | (5.58 to 12.59) | 8.47 | (5.07 to 11.86) | 6.53 | (3.00 to 10.06) |
PFMT: Pelvic floor muscle training; HE: Hypopressive exercise; PFMT+HE: Pelvic floor muscle training and hypopressive exercise; CI: Confidence Interval; PFDI-20: Pelvic floor Distress Inventory Short Form; POPDI: Pelvic organ prolapse distress inventory; UDI: Urinary distress inventory; CRADI: Colo-rectal-anal distress inventory; PFQ−7: Pelvic Floor Impact Questionnaire Short Form; POPIQ: Prolapse impact questionnaire; CRAIQ: Colo-rectal-anal impact questionnaire; UIQ: Urinary impact questionnaire. The mean and CI that did not show significant differences against A0 are highlighted in bold.
Figure 2(A): changes in PFDI-20: Pelvic floor Distress Inventory Short Form outcome from baseline; (B): changes in PFIQ-7: Pelvic Floor Impact Questionnaire Short Form outcome from baseline.
Figure 3(3): changes in pelvic floor muscle strength measured by manometry outcome from baseline; (3): changes in pelvic floor muscle strength measured by dynamometry outcome from baseline; (3): changes in basal tone outcome from baseline.
Mean differences between intervention groups across 4 follow-up assessments.
| Variable | (HE-G)–(PFMT-G) | (PFMT+HE-G)–(PFMT-G) | ||
|---|---|---|---|---|
| Mean Diff. | Mean Diff. | |||
| PFDI-20 | −0.54 | 0.9326 | 11.67 | 0.0703 |
| POPDI | −0.06 | 0.9785 | 3.83 | 0.0935 |
| CRADI | −0.26 | 0.9040 | 3.09 | 0.1535 |
| UDI | 0.59 | 0.8503 | 4.82 | 0.1233 |
| PFIQ-7 | 1.95 | 0.6675 |
|
|
| POPIQ | 1.05 | 0.6175 |
|
|
| CRAIQ | 1.64 | 0.2768 |
|
|
| UIQ | −0.84 | 0.7119 | 1.81 | 0.4260 |
| Manometry | −1.44 | 0.5280 | −0.04 | 0.9844 |
| Dynamometry | −86.07 | 0.0887 | −72.63 | 0.1481 |
| Basal tone | 1.04 | 0.7721 | 2.87 | 0.4333 |
PFMT-G: Pelvic floor muscle training group; HE-G: Hypopressive exercise group; PFMT+HE-G: Pelvic floor muscle training and hypopressive exercise group; diff: Difference; PFDI-20: Pelvic floor Distress Inventory Short Form; POPDI: Pelvic organ prolapse distress inventory; UDI: Urinary distress inventory; CRADI: Colo-rectal-anal distress inventory; PFIQ-7: Pelvic Floor Impact Questionnaire Short Form; POPIQ: Prolapse impact questionnaire; CRAIQ: Colo-rectal-anal impact questionnaire; UIQ: Urinary impact questionnaire. Average differences between groups that showed p-values < 0.05 are highlighted in bold.